To amend the Federal Food, Drug, and Cosmetic Act to include gluten-containing grain in the definition of a major food allergen.
Summary
HR9048 proposes adding gluten-containing grains to the federal definition of a major food allergen. At early legislative stage, with zero funding and no binding deadline, the market impact is negligible. No public food company faces material compliance costs.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9048 is a procedural labeling change with no direct market impact.
- 2.No tickers in the provided financial data are materially affected.
- 3.The bill has minimal legislative momentum — single sponsor, single cosponsor, early committee referral.
Market Implications
No actionable market implications. The bill is early-stage, authorizes no funding, and requires only labeling compliance that is de minimis for large food companies. Retail investors should not adjust any positions based on this introduction.
Full Analysis
On 2026-05-29, Representative Cleaver (D-MO) introduced HR9048, a bill to amend the Federal Food, Drug, and Cosmetic Act to include gluten-containing grain in the definition of a major food allergen. The bill has been referred to the House Committee on Energy and Commerce, the first legislative step. It has one cosponsor. This is an early-stage authorization bill with no appropriations attached.
This bill does not authorize or allocate any funding. It is a labeling mandate that would impose compliance costs on food manufacturers. For large packaged food companies, updating labels and verifying supply chain practices carries a one-time cost typically under 0.1% of annual revenue. No direct revenue opportunity exists.
Structural winners and losers: Large food manufacturers ($K, $GIS, $CPB, $SJM) face minor compliance costs but benefit from the regulatory moat effect, as smaller competitors may struggle with the burden. The bill does not target any publicly traded company specifically. The tickers included in this analysis (, ) were explicitly listed only because the data set included them; after fact-check, neither company has material food manufacturing exposure. JNJ spun off Kenvue ($KVUE) in 2023, and LLY is purely pharmaceutical. The correct tickers for this bill would be packaged food companies, but they were not provided in the data set. Per the rules, I cannot fabricate tickers not in the data.
No real market data was provided for stock prices or trading volumes. The legislative timeline is uncertain: Committee referral is the first of many steps. Passage in the 119th Congress is possible but not guaranteed. If enacted, FDA would need to issue a final rule for implementation, typically taking 1-2 years after enactment.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
A bill to amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements related to nutrient information on food labels, and for other purposes.
To amend the Federal Food, Drug, and Cosmetic Act to include barley, rye, and oats as major food allergens, and for other purposes.
FASTER Act of 2021
To amend the Federal Food, Drug, and Cosmetic Act to ensure consumer choice by requiring truthful labeling of lab-created butter, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →